ES2094004T3 - Uretanos y ureas que inducen la produccion de citoquinas. - Google Patents

Uretanos y ureas que inducen la produccion de citoquinas.

Info

Publication number
ES2094004T3
ES2094004T3 ES94106123T ES94106123T ES2094004T3 ES 2094004 T3 ES2094004 T3 ES 2094004T3 ES 94106123 T ES94106123 T ES 94106123T ES 94106123 T ES94106123 T ES 94106123T ES 2094004 T3 ES2094004 T3 ES 2094004T3
Authority
ES
Spain
Prior art keywords
ureas
urethans
cytokines
induce
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94106123T
Other languages
English (en)
Inventor
Semiramis Ayral-Kaloustian
Steven R Schow
Mila T Du
James J Gibbons Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ES2094004T3 publication Critical patent/ES2094004T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

LA INVENCION ES RELATIVA A NUEVAS UREAS Y URETANOS DE FORMULA I: QUE ESTIMULA LA PRODUCCION DE CITOQUINA Y PUEDEN SER USADAS PARA ACELERAR LA RECUPERACION DE NEUTROPENIA ACOMPAÑADAS DE RADIOCIONES. COMPUESTOS DE LA INVENCION O COMPOSICIONES FARMACEUTICAS QUE EMPLEAN ESTOS COMPUESTOS PUEDEN SER USADOS EN EL TRATAMIENTO DE CANCER, SIDA, ANEMIA APLASICA, SINDROME MIELODISPLASICO, Y EN LA MEJORA DE RESPUESTA INMUNE.
ES94106123T 1993-05-12 1994-04-20 Uretanos y ureas que inducen la produccion de citoquinas. Expired - Lifetime ES2094004T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/063,174 US5312831A (en) 1993-05-12 1993-05-12 Urethanes and ureas that induce cytokine production

Publications (1)

Publication Number Publication Date
ES2094004T3 true ES2094004T3 (es) 1997-01-01

Family

ID=22047440

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94106123T Expired - Lifetime ES2094004T3 (es) 1993-05-12 1994-04-20 Uretanos y ureas que inducen la produccion de citoquinas.

Country Status (26)

Country Link
US (6) US5312831A (es)
EP (1) EP0652228B1 (es)
JP (1) JP3583469B2 (es)
KR (1) KR100296543B1 (es)
CN (1) CN1094943C (es)
AT (1) ATE144533T1 (es)
AU (1) AU669064B2 (es)
CA (1) CA2123261A1 (es)
CZ (1) CZ290445B6 (es)
DE (1) DE69400798T2 (es)
DK (1) DK0652228T3 (es)
ES (1) ES2094004T3 (es)
FI (1) FI942186A (es)
GR (1) GR3022253T3 (es)
HU (1) HU219768B (es)
IL (1) IL109602A (es)
NO (1) NO311223B1 (es)
NZ (1) NZ260507A (es)
PH (1) PH30182A (es)
PL (1) PL179984B1 (es)
RU (1) RU2135515C1 (es)
SG (1) SG43071A1 (es)
SI (1) SI0652228T1 (es)
SK (1) SK281120B6 (es)
TW (1) TW380129B (es)
ZA (1) ZA943266B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1007183A3 (fr) * 1993-06-18 1995-04-18 Solvay Ureines derivees d'alpha, omega-diaminoacides et procede pour leur preparation.
EP0809492A4 (en) * 1995-02-17 2007-01-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
US6005008A (en) * 1996-02-16 1999-12-21 Smithkline Beecham Corporation IL-8 receptor antagonists
US6211373B1 (en) 1996-03-20 2001-04-03 Smithkline Beecham Corporation Phenyl urea antagonists of the IL-8 receptor
US6262113B1 (en) 1996-03-20 2001-07-17 Smithkline Beecham Corporation IL-8 receptor antagonists
EP0912505A4 (en) * 1996-06-27 2001-10-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
AU3499497A (en) 1996-06-27 1998-01-14 Smithkline Beecham Corporation Il-8 receptor antagonists
EP0939634A4 (en) * 1996-08-15 2001-02-21 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
WO1999050238A1 (fr) * 1998-03-26 1999-10-07 Santen Pharmaceutical Co., Ltd. Nouveaux derives d'uree
US7465754B1 (en) 1999-09-15 2008-12-16 Wyeth Method of potentiating chemotherapy and treating solid tumors
US7332158B2 (en) 2002-05-29 2008-02-19 Demao Yang Compositions and treatments for myelosuppression by ex vivo activated immune cells
US7048922B2 (en) * 2002-05-29 2006-05-23 Demao Yang Stimulation of hematopoiesis by ex vivo activated immune cells
AR041834A1 (es) * 2002-10-29 2005-06-01 Smithkline Beecham Corp Compuesto de difenilurea sustituido con sulfonamida, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
US20060057121A1 (en) * 2004-09-10 2006-03-16 Demao Yang Compositions and treatments using ex vivo activated cells for myelosuppressed patients
DK2009992T3 (da) * 2006-04-21 2012-08-13 Glaxosmithkline Llc Il-8 receptor-antagonister
CA2650007A1 (en) * 2006-04-21 2007-11-01 Smithkline Beecham Corporation Il-8 receptor antagonists
AR061571A1 (es) * 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto sal del acido toluenosulfonico de 4-{[6-cloro-3-({[(2- cloro-3-fluorofenil) amino]carbonil} amino)- 2- hidroxifenil]sulfonil] -1- piperazinacarbxilato de 1.1-dimetiletilo, composicion farmaceutica que lo comprende su uso para la fabricacion de un medicamento combinacion farmaceutica con un
WO2013149025A1 (en) * 2012-03-30 2013-10-03 Givaudan, S., A. N-acyl serine derivatives as food flavouring compounds
EP2830439B1 (en) 2012-03-30 2020-11-04 Givaudan SA N-acyl-gaba derivatives for the improvement of the flavour profile of edible compositions
SG11201405409PA (en) 2012-03-30 2014-11-27 Givaudan Sa N-acylated 1 - aminocycloalkyl carboxylic acids as food flavouring compounds
BR112014023941B1 (pt) 2012-03-30 2020-07-14 Givaudan S.A. Composição flavorizante em pó, bem como composições comestíveis de petisco e refresco em pó compreendendo a mesma
CN104219964B (zh) 2012-03-30 2016-09-21 奇华顿股份有限公司 作为食品加香化合物的n-酰基脯氨酸衍生物
US10836712B2 (en) 2012-03-30 2020-11-17 Givaudan S.A. Organic compounds
JP6248091B2 (ja) 2012-03-30 2017-12-13 ジボダン エス エー 食品フレーバー付与化合物としてのガンマアミノ酪酸およびベータアラニンのｎ−アシル誘導体
CA2868058C (en) 2012-03-30 2019-12-17 Givaudan S.A. N-acylated methionine derivatives as food flavouring compounds
US10537127B2 (en) 2013-10-02 2020-01-21 Givaudan S.A. Organic compounds
EP3057445B1 (en) 2013-10-02 2018-07-04 Givaudan SA Organic compounds having taste-modifying properties
WO2015050535A1 (en) 2013-10-02 2015-04-09 Givaudan S.A. Organic compounds
CN105636459A (zh) 2013-10-02 2016-06-01 奇华顿股份有限公司 有机化合物
WO2015050538A1 (en) 2013-10-02 2015-04-09 Givaudan S.A. Organic compounds
GB201317424D0 (en) * 2013-10-02 2013-11-13 Givaudan Sa Improvements in or relating to organic compounds
US11122826B2 (en) 2013-10-02 2021-09-21 Givaudan Sa Organic compounds
US20160227825A1 (en) 2013-10-02 2016-08-11 Givaudan Sa Organic Compounds having Taste-Modifying Properties
MX2020002010A (es) 2017-08-21 2020-07-13 Celgene Corp Procesos para la preparacion de 4,5-diamino-5-oxopentanoato de (s)-terc-butilo.
CN109601739B (zh) * 2019-01-17 2022-10-14 河南湾流生物科技有限公司 一种复合氨基酸饲料添加剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2033906B (en) * 1978-10-19 1982-12-01 Anvar Water-soluble compounds derived from extracts of streptomyces stimulosus process for their production and compositions containing them
US4725582A (en) * 1978-11-14 1988-02-16 Fujisawa Pharmaceutical Company, Ltd. Peptide, process for preparation thereof and use thereof
US4349466A (en) * 1978-11-14 1982-09-14 Fujisawa Pharmaceutical Co Peptide, process for preparation thereof and use thereof
FR2460290A1 (fr) * 1979-06-29 1981-01-23 Rhone Poulenc Ind Nouveaux tetra- ou pentapeptides, leur preparation et les medicaments qui les contiennent
CA2116684A1 (en) * 1991-09-27 1993-04-01 Robert G. Kilbourn Amino acids containing parenteral formulations for the treatment of hypotension and related pathologies

Also Published As

Publication number Publication date
CN1100413A (zh) 1995-03-22
SI0652228T1 (en) 1997-10-31
JP3583469B2 (ja) 2004-11-04
ZA943266B (en) 1995-01-12
IL109602A0 (en) 1994-08-26
CN1094943C (zh) 2002-11-27
SK281120B6 (sk) 2000-12-11
EP0652228A1 (en) 1995-05-10
US5658945A (en) 1997-08-19
KR100296543B1 (ko) 2001-11-22
EP0652228B1 (en) 1996-10-23
HUT67038A (en) 1995-01-30
US5633280A (en) 1997-05-27
SK49194A3 (en) 1995-02-08
CA2123261A1 (en) 1994-11-13
HU9401444D0 (en) 1994-08-29
SG43071A1 (en) 1997-10-17
PL179984B1 (pl) 2000-11-30
FI942186A (fi) 1994-11-13
JPH07179414A (ja) 1995-07-18
AU669064B2 (en) 1996-05-23
US5545662A (en) 1996-08-13
IL109602A (en) 2000-06-01
FI942186A0 (fi) 1994-05-11
US5602275A (en) 1997-02-11
NO311223B1 (no) 2001-10-29
RU2135515C1 (ru) 1999-08-27
NZ260507A (en) 1996-02-27
CZ98194A3 (en) 1994-12-15
CZ290445B6 (cs) 2002-07-17
DK0652228T3 (da) 1996-11-25
HU219768B (hu) 2001-07-30
NO941786D0 (no) 1994-05-11
TW380129B (en) 2000-01-21
DE69400798D1 (de) 1996-11-28
AU6304394A (en) 1994-11-17
DE69400798T2 (de) 1997-03-13
PH30182A (en) 1997-01-21
US5616612A (en) 1997-04-01
NO941786L (no) 1994-11-14
ATE144533T1 (de) 1996-11-15
US5312831A (en) 1994-05-17
GR3022253T3 (en) 1997-04-30

Similar Documents

Publication Publication Date Title
ES2094004T3 (es) Uretanos y ureas que inducen la produccion de citoquinas.
RU94016389A (ru) Карбаматы и карбамиды, индуцирующие производство цитокинов
DK0604418T3 (da) Isolerede viralproteincytokinantagonister
ES2063278T3 (es) Proteina morfogenetica de hueso.
IL150223A (en) Lipopeptides and pharmaceuticals containing them
CY1107351T1 (el) Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης
NO20035211D0 (no) Faste farmasöytiske formuleringer omfattende modafinil
IL196900A (en) Autologous T cell vaccine compositions
BR0211761A (pt) depsipeptìdeos e processos para preparar os mesmos
SE0203825D0 (sv) Novel fused heterocycles and uses thereof
PT1082131E (pt) Imuno-regulador
TW200500097A (en) Novel pharmaceutical formulations of modafinil
ATE213233T1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
CY1109206T1 (el) gM- ΑΡΝΗΤΙΚΟΙ EHV-ΜΕΤΑΛΛΑΚΤΕΣ ΧΩΡΙΣ ΕΤΕΡΟΛΟΓΑ ΣΤΟΙΧΕΙΑ
IS7940A (is) Samsetningar sem samanstanda af fósturblóðrauða og bakteríuinneitri og mögulega viðbótar hlutum fósturlifrar
ES2142840T3 (es) Proteina que se une al interferon alfa/beta, su preparacion y las composiciones farmaceuticas que la contienen.
WO2024077118A3 (en) Multispecific proteins and related methods
SE9902147D0 (sv) Nya föreningar och farmaceutiska kompositioner innehållande desamma

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 652228

Country of ref document: ES